Oncquest blood home pickup

  • patients
  • doctors
  • care givers

Clinical utility

View / Download

  • Predict risk of recurrence in ER+, HER2- early stage (I/II) patients with Invasive ductal carcinoma (IDC) of breast and also aids in the Chemotherapy treatment decision.
  • The test can stratify node negative (NO) and node-positive (NP) patients effectively across all ages, including early onset (<45 years) patients as well.
  • This is the only test developed and validated on Indian patients.
  • Results are binary (high risk or Low risk) with no intermediate risk zone, making it easier for physicians to make clinical decisions.
  • The test has better prognostic ability when compared with Ki-67, PREDICT, IHC4 and showed good concordance with Oncotype Dx.

Eligibility criteria for CanAssist-Breast

  • Patients with invasive ductal breast carcinoma
  • Hormone receptor -positive (ER+, PR+/-)
  • Her2neu receptor – negative (Her2-)
  • Up to T3 tumor size
  • Up to N1 (3 lymphnode positive)

Exclusion criteria for CanAssist-Breast

  • ER- patients
  • HER2+ patients
  • Triple negative (TNBC) patients
  • Patients treated with neo-adjuvant chemotherapy/hormone therapy